Overview
- A single 240 mg dose of WVE-007 cut visceral fat by 9.4%, reduced total fat by 4.5%, and increased lean mass by 3.2% at three months in the lowest therapeutic cohort, with no lifestyle changes in the study.
- Placebo participants showed no significant shifts, and overall body weight change was minimal at this interim readout because lean mass gains offset fat loss.
- Activin E fell by as much as 78% at Day 43 and averaged more than 75% suppression through Day 85 after one dose, aligning with on-target biology.
- WVE-007 was generally safe and well-tolerated to date up to 600 mg with no discontinuations and no severe or serious treatment-emergent adverse events.
- Shares more than doubled to new highs Monday and rose again Tuesday as Wave launched a $250 million underwritten offering with a 30-day overallotment option, while analysts lifted ratings and targets and higher-dose cohort readouts are slated for Q1–Q2 2026.